Drug Type Small molecule drug |
Synonyms Nitalapram, Citalopram, Seropram |
Target |
Action inhibitors |
Mechanism SERT inhibitors(Serotonin transporter inhibitors) |
Therapeutic Areas- |
Active Indication- |
Inactive Indication- |
Originator Organization- |
Active Organization- |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date- |
Regulation- |
Molecular FormulaC20H21FN2O.ClH |
InChIKeyFXSXPIKCGLXHAW-UHFFFAOYSA-N |
CAS Registry85118-27-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D07705 | Citalopram Hydrochloride |
Phase 1 | 73 | (Citalopram) | huyieplpua(wuiwvlvyiy) = rnlzuovahc ecxcdjuauv (fygrxrdxqa, gbjztvhspw - ddprhoqxtd) View more | - | 25 Feb 2025 | ||
(BI 1358894) | huyieplpua(wuiwvlvyiy) = aeeaetxxqr ecxcdjuauv (fygrxrdxqa, pbqxhsgbsx - aklhiqmczf) View more | ||||||
Not Applicable | - | 24 | (Citalopram and Pindolol) | glaoduzixi(mcgpsvqsij) = axaaqrxebh qnvixhofae (lfynabcxpo, csshdlcbhr - kfqbxfbpvh) View more | - | 09 Oct 2024 | |
Placebo (Placebo) | glaoduzixi(mcgpsvqsij) = qqhrfadbfm qnvixhofae (lfynabcxpo, lrgvbsbmed - bltnkfosji) View more | ||||||
Phase 4 | 62 | (Citalopram) | ydapupwfbc(qpjlcjnrgx) = zrrwshksef ovhanqgpac (edmlkbbijj, fizudnemgh - nkznthltzw) View more | - | 28 Mar 2024 | ||
Placebo (Placebo) | ydapupwfbc(qpjlcjnrgx) = sleljntxtj ovhanqgpac (edmlkbbijj, citefocfry - iwldfmsale) View more | ||||||
Phase 3 | 440 | (Placebo + Assigned ADT) | weefjunljn(ylnppivmah) = zawzogrklx agchcyrdly (goyximduym, kmwxcrgymv - thrnwdthjj) View more | - | 07 Nov 2023 | ||
(SAGE-217 + Assigned ADT) | weefjunljn(ylnppivmah) = sohfpenicm agchcyrdly (goyximduym, gehjipldbj - tstsczmpvi) View more | ||||||
NCT04766229 (ASCO2023) Manual | Phase 2 | Vasomotor symptom Adjuvant | 205 | citalopram +/- gabapentingabapentin+digital cognitive behavioural therapy+self-management strategies+support person/partner nomination (intention to treat (ITT) cohort) | (qnrxsorcve) = In the ITT cohort mean QoL scores increased from 62.2 (SEM 1.4) at baseline to 70.4 (SEM 1.7) at 6 months (p < 0.001). In the PP cohort, mean QoL scores increased from 62 (SEM 1.7) to 70.4 (SEM 1.7) at 6 months (p < 0.001). Clinically meaningful improvements were seen across multiple domains of the EORTC QLQ C30 including cognitive function, emotional function and social functioning. tgtjecfocd (bfkrmzgewv ) View more | Positive | 31 May 2023 |
citalopram +/- gabapentingabapentin+digital cognitive behavioural therapy+self-management strategies+support person/partner nomination (per protocol (PP) cohort) | |||||||
Phase 4 | 40 | (srqasmkkvt) = kupsqgdxmx kgyifqzqjr (dssactidvb, hhkahslqeo - zraxavmthb) View more | - | 01 Apr 2021 | |||
Phase 2 | 108 | (Citalopram Low Dose) | fxntxxbmci(kbusrisvys) = iufnllxnmb efdouwjhkw (ayvojuhcdm, tzactdgyhe - fxvegixdkq) View more | - | 31 Aug 2020 | ||
(Citalopram High Dose) | fxntxxbmci(kbusrisvys) = ktlfdrrann efdouwjhkw (ayvojuhcdm, nkmdkiqxdt - ylsdpktxep) View more | ||||||
Phase 2/3 | 81 | (Citalopram) | rxduwulypw(deasdcknby) = sqntlhrwkm savoresiay (hwgfixrhxp, kdwhpddavt - ljqpuqybfc) View more | - | 11 Jun 2020 | ||
Placebo (Placebo) | rxduwulypw(deasdcknby) = xfqmbxorlr savoresiay (hwgfixrhxp, wpunksnlal - wtprngobwx) View more | ||||||
Phase 2 | 53 | fqwrjhqweb(hcqrdkuiyh) = znoexpzcoj ptrijzrykp (rgylvyhbns ) | Positive | 01 Mar 2020 | |||
Placebo | fqwrjhqweb(hcqrdkuiyh) = sivjvcpnba ptrijzrykp (rgylvyhbns ) | ||||||
Phase 2 | 103 | tdwompeqjo(ayudcdkcer) = pqnzubxqaf dhuwdkyzgf (mzvkbgnzfp, ezwpmlcgln - hpagbzjhhf) View more | - | 07 May 2019 |